Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Identifieur interne : 007A21 ( Main/Exploration ); précédent : 007A20; suivant : 007A22Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Auteurs : Jean-Luc Harousseau [France] ; Meletios A. Dimopoulos [Grèce] ; Michael Wang [États-Unis] ; Alessandro Corso [Italie] ; Christine Chen [Canada] ; Michel Attal [France] ; Andrew Spencer [Australie] ; ZHINUAN YU [États-Unis] ; Marta Olesnyckyj [États-Unis] ; Jerome B. Zeldis [États-Unis] ; Robert D. Knight [États-Unis] ; Donna M. Weber [États-Unis]Source :
- Haematologica : (Roma) [ 0390-6078 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved. Conclusions Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.
Url:
Affiliations:
- Australie, Canada, France, Grèce, Italie, États-Unis
- Attique (région), Midi-Pyrénées, Occitanie (région administrative), Victoria (État)
- Athènes, Melbourne, Toulouse
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002266
- to stream PascalFrancis, to step Curation: 003D28
- to stream PascalFrancis, to step Checkpoint: 002588
- to stream Main, to step Merge: 008056
- to stream Pmc, to step Corpus: 001851
- to stream Pmc, to step Curation: 001711
- to stream Pmc, to step Checkpoint: 002642
- to stream Ncbi, to step Merge: 000785
- to stream Ncbi, to step Curation: 000785
- to stream Ncbi, to step Checkpoint: 000785
- to stream Main, to step Merge: 007529
- to stream Main, to step Curation: 007A21
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma</title>
<author><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre René Gauducheau, Bd Jacques Monod</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Bd Jacques Monod</wicri:noRegion>
<wicri:noRegion>Centre René Gauducheau, Bd Jacques Monod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, University of Athens School of Medicine</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Michael" sort="Wang, Michael" uniqKey="Wang M" first="Michael" last="Wang">Michael Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>M.D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>M.D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Corso, Alessandro" sort="Corso, Alessandro" uniqKey="Corso A" first="Alessandro" last="Corso">Alessandro Corso</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia</s1>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chen, Christine" sort="Chen, Christine" uniqKey="Chen C" first="Christine" last="Chen">Christine Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Attal, Michel" sort="Attal, Michel" uniqKey="Attal M" first="Michel" last="Attal">Michel Attal</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Division of Hematology, Centre Hospitalier Université de Purpan</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Alfred Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhinuan Yu" sort="Zhinuan Yu" uniqKey="Zhinuan Yu" last="Zhinuan Yu">ZHINUAN YU</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Olesnyckyj, Marta" sort="Olesnyckyj, Marta" uniqKey="Olesnyckyj M" first="Marta" last="Olesnyckyj">Marta Olesnyckyj</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeldis, Jerome B" sort="Zeldis, Jerome B" uniqKey="Zeldis J" first="Jerome B." last="Zeldis">Jerome B. Zeldis</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knight, Robert D" sort="Knight, Robert D" uniqKey="Knight R" first="Robert D." last="Knight">Robert D. Knight</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weber, Donna M" sort="Weber, Donna M" uniqKey="Weber D" first="Donna M." last="Weber">Donna M. Weber</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>M.D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>M.D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0503657</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0503657 INIST</idno>
<idno type="RBID">Pascal:10-0503657</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002266</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003D28</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002588</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002588</idno>
<idno type="wicri:doubleKey">0390-6078:2010:Harousseau J:better:quality:of</idno>
<idno type="wicri:Area/Main/Merge">008056</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948100</idno>
<idno type="RBID">PMC:2948100</idno>
<idno type="wicri:Area/Pmc/Corpus">001851</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001851</idno>
<idno type="wicri:Area/Pmc/Curation">001711</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001711</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002642</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002642</idno>
<idno type="wicri:Area/Ncbi/Merge">000785</idno>
<idno type="wicri:Area/Ncbi/Curation">000785</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000785</idno>
<idno type="wicri:doubleKey">0390-6078:2010:Harousseau J:better:quality:of</idno>
<idno type="wicri:Area/Main/Merge">007529</idno>
<idno type="wicri:Area/Main/Curation">007A21</idno>
<idno type="wicri:Area/Main/Exploration">007A21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma</title>
<author><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre René Gauducheau, Bd Jacques Monod</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Bd Jacques Monod</wicri:noRegion>
<wicri:noRegion>Centre René Gauducheau, Bd Jacques Monod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical Therapeutics, University of Athens School of Medicine</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Michael" sort="Wang, Michael" uniqKey="Wang M" first="Michael" last="Wang">Michael Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>M.D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>M.D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Corso, Alessandro" sort="Corso, Alessandro" uniqKey="Corso A" first="Alessandro" last="Corso">Alessandro Corso</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia</s1>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chen, Christine" sort="Chen, Christine" uniqKey="Chen C" first="Christine" last="Chen">Christine Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Attal, Michel" sort="Attal, Michel" uniqKey="Attal M" first="Michel" last="Attal">Michel Attal</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Division of Hematology, Centre Hospitalier Université de Purpan</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Alfred Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhinuan Yu" sort="Zhinuan Yu" uniqKey="Zhinuan Yu" last="Zhinuan Yu">ZHINUAN YU</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Olesnyckyj, Marta" sort="Olesnyckyj, Marta" uniqKey="Olesnyckyj M" first="Marta" last="Olesnyckyj">Marta Olesnyckyj</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeldis, Jerome B" sort="Zeldis, Jerome B" uniqKey="Zeldis J" first="Jerome B." last="Zeldis">Jerome B. Zeldis</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knight, Robert D" sort="Knight, Robert D" uniqKey="Knight R" first="Robert D." last="Knight">Robert D. Knight</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Celgene Corporation</s1>
<s2>Summit, NJ</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Celgene Corporation</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weber, Donna M" sort="Weber, Donna M" uniqKey="Weber D" first="Donna M." last="Weber">Donna M. Weber</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>M.D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>M.D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Haematologica : (Roma)</title>
<title level="j" type="abbreviated">Haematologica : (Roma)</title>
<idno type="ISSN">0390-6078</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Haematologica : (Roma)</title>
<title level="j" type="abbreviated">Haematologica : (Roma)</title>
<idno type="ISSN">0390-6078</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Clinical benefit</term>
<term>Dexamethasone</term>
<term>Hematology</term>
<term>Human</term>
<term>Lenalidomide</term>
<term>Myeloma</term>
<term>Prognosis</term>
<term>Quality</term>
<term>Relapse</term>
<term>Treatment efficiency</term>
<term>Treatment resistance</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lénalidomide</term>
<term>Qualité</term>
<term>Pronostic</term>
<term>Dexaméthasone</term>
<term>Homme</term>
<term>Récidive</term>
<term>Myélome</term>
<term>Résistance traitement</term>
<term>Efficacité traitement</term>
<term>Hématologie</term>
<term>Anticancéreux</term>
<term>Bénéfice clinique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved. Conclusions Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Grèce</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Attique (région)</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Athènes</li>
<li>Melbourne</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><country name="France"><noRegion><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name>
</noRegion>
<name sortKey="Attal, Michel" sort="Attal, Michel" uniqKey="Attal M" first="Michel" last="Attal">Michel Attal</name>
</country>
<country name="Grèce"><region name="Attique (région)"><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Wang, Michael" sort="Wang, Michael" uniqKey="Wang M" first="Michael" last="Wang">Michael Wang</name>
</noRegion>
<name sortKey="Knight, Robert D" sort="Knight, Robert D" uniqKey="Knight R" first="Robert D." last="Knight">Robert D. Knight</name>
<name sortKey="Olesnyckyj, Marta" sort="Olesnyckyj, Marta" uniqKey="Olesnyckyj M" first="Marta" last="Olesnyckyj">Marta Olesnyckyj</name>
<name sortKey="Weber, Donna M" sort="Weber, Donna M" uniqKey="Weber D" first="Donna M." last="Weber">Donna M. Weber</name>
<name sortKey="Zeldis, Jerome B" sort="Zeldis, Jerome B" uniqKey="Zeldis J" first="Jerome B." last="Zeldis">Jerome B. Zeldis</name>
<name sortKey="Zhinuan Yu" sort="Zhinuan Yu" uniqKey="Zhinuan Yu" last="Zhinuan Yu">ZHINUAN YU</name>
</country>
<country name="Italie"><noRegion><name sortKey="Corso, Alessandro" sort="Corso, Alessandro" uniqKey="Corso A" first="Alessandro" last="Corso">Alessandro Corso</name>
</noRegion>
</country>
<country name="Canada"><noRegion><name sortKey="Chen, Christine" sort="Chen, Christine" uniqKey="Chen C" first="Christine" last="Chen">Christine Chen</name>
</noRegion>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007A21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007A21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:10-0503657 |texte= Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma }}
This area was generated with Dilib version V0.6.33. |